Dachaigh › Cancer briste triple-negative › Texas › Houston
Sgrùdaidhean clionaigeach Cancer briste triple-negative ann an Houston, TX
Tha 42 sgrùdaidhean airson Cancer briste triple-negative a’ lorg phàirtichean aig làraichean ann agus timcheall air Houston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A’ fastadhÌre 1
- University of Texas MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
A’ fastadhÌre 1/2
- MD Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
A’ fastadh
- M D Anderson Cancer Center, Houston
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
A’ fastadhÌre 3
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- Kelsey-Seybold Clinic ( Site 0040), Houston
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A’ fastadhÌre 3
- Oncology Consultants P.A. ( Site 0107), Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A’ fastadhÌre 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Intratumoral N17350 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A’ fastadhÌre 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
A’ fastadhÌre 2
- Baylor College of Medicine, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A’ fastadhÌre 3
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
A’ fastadhÌre 1
- The University of Texas - MD Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A’ fastadhSgrùdadh amharc
- UT Health Houston, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
A’ fastadhÌre 1
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
A’ fastadhÌre 1/2
- MD Anderson Cancer Center, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
A’ fastadhÌre 1
- UT MD Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A’ fastadhÌre 2/3
- (USOR) Texas Oncology, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
A’ fastadhÌre 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
A’ fastadhÌre 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A’ fastadhÌre 1/2
- MD Anderson, Houston
A Study of LY4175408 in Participants With Advanced Cancer
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Study of XB010 in Subjects With Solid Tumors
A’ fastadhÌre 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
A’ fastadhÌre 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
A’ fastadhÌre 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
A’ fastadhÌre 1/2
- M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
A’ fastadhÌre 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
A’ fastadhÌre 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A’ fastadhSgrùdadh amharc
- The University of Texas MD Anderson Cancer Center, Houston
Sgrùdaidhean Cancer briste triple-negative ann am bailtean eile
- New York City, NY31 sgrùdaidhean
- Nashville, TN28 sgrùdaidhean
- Los Angeles, CA27 sgrùdaidhean
- Boston, MA26 sgrùdaidhean
- San Antonio, TX23 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
- Arlington, VA20 sgrùdaidhean
- Atlanta, GA20 sgrùdaidhean
- Dallas, TX18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Columbus, OH16 sgrùdaidhean
- Grand Rapids, MI15 sgrùdaidhean
Sgrùdaidhean eile ann an Houston
- Aillse Sgamhain Neo-chealla-beag145 sgrùdaidhean
- Aillse a' bhroilleach126 sgrùdaidhean
- Aillse (gach seòrsa)121 sgrùdaidhean
- Ailse metastatach104 sgrùdaidhean
- Aillse colorectal102 sgrùdaidhean
- Cancer Ovarian89 sgrùdaidhean
- Leukemia myeloid geur85 sgrùdaidhean
- Ailseachadh nan Sgamhan78 sgrùdaidhean
- Aillse Prostata76 sgrùdaidhean
- Ailse Endometrial68 sgrùdaidhean
- Cancer Pancreatic61 sgrùdaidhean
- Melanoma59 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.